VPAC2 receptor agonist BAY 55-9837 increases SMN protein levels and moderates disease phenotype in severe spinal muscular atrophy mouse models.

Hadwen, Jeremiah

VPAC2 receptor agonist BAY 55-9837 increases SMN protein levels and moderates disease phenotype in severe spinal muscular atrophy mouse models. [electronic resource] - Orphanet journal of rare diseases Jan 2014 - 4 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1750-1172

10.1186/1750-1172-9-4 doi


Animals
Disease Models, Animal
Mice
Muscular Atrophy, Spinal--drug therapy
Peptide Fragments--therapeutic use
Receptors, Vasoactive Intestinal Peptide, Type II--agonists
Survival of Motor Neuron 1 Protein--metabolism
Vasoactive Intestinal Peptide--therapeutic use